Objective: To discuss the effect of Danhong Huayu oral on levels of vascular endothelial growth factor (VEGF)

angiopoietin protein and angiopoietin in patients of non-proliferative diabetic retinopathy (NPDR) with collaterals stagnation syndrome. Method: One hundred and twenty-nine NPDR patients were randomly divided into control group (64 cases

115 eyes) and observation group (65 cases

116 eyes) by random number table. Patients in control group took dobesilate calcium capsules

0.5 g/time

3 times/day

pancreatic kallikrein enteric-coated tablets

1 tablet/time

3 times/day. In addition to the therapy of control group

observation group was also given Danhong Huayu oral

20 mL/time

3 times/day. Courses of treatment were 12 weeks. Vision

intraocular pressure and fundus examination after dilated were detected. Scores of collaterals stagnation syndrome were graded. Optical coherence tomography (OCT) and fundus fluorescein angiography were conducted. Before and after treatment

levels of Angiopoietin-2 (Ang-2)

Angiopoietin-1 (Ang-1)

Angiopoietin protein-3 (ANGPT-3)

Angiopoietin protein-4 (ANGPT-4) and VEGF were detected. Result: After treatment

vision in observation group was better than that in control group (P<0.05)

and scores of macular edema and ollaterals stagnation syndrome were lower than those in control group (P<0.01). Foveal thickness and macular volume in observation group were lower than those in control group (P<0.05). Retinal vascular leakage area and etinal capillary non-perfusion area in observation group were less than those in control group (P<0.01)

the number of tumor microvessels and arm retinal circulation time were less and shorter than those in control group (P<0.05). Levels of VEGF

ANGPT-3 and Ang-2 were lower than those in control group

while ANGPT-4 and Ang-1 were higher than those in control group (P<0.01). Conclusion: Danhong Huayu oral can improve patients' vision

relieve edema caused by macular

ameliorate retinal circulatory disorders

and regulate VEGF

ANGPT-3/ANGPT-4 and Ang-1/Ang-2

inhibit generating new blood vessels

and delay progression of NPDR.